The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth.
Despite investigations into mechanisms linking type 2 diabetes and cancer, there is a gap in knowledge about pharmacotherapy for diabetes in cancer patients. Epidemiological studies have shown that diabetic cancer patients on different antidiabetic treatments have different survival. The clinically relevant question is whether some antidiabetic pharmacotherapeutic agents promote cancer whereas others inhibit cancer progression. We investigated the hypothesis that various antidiabetic drugs had differential direct impact on cancer cells using four human cell lines (pancreatic cancer: MiaPaCa2, Panc-1; breast cancer: MCF7, HER18). We found that insulin and glucose promoted cancer cell proliferation and contributed to chemoresistance. Metformin and rosiglitazone suppressed cancer cell growth and induced apoptosis. Both drugs affected signalling in the protein kinases B (AKT)/mammalian target of rapamycin pathway; metformin activated adenosine monophosphate (AMP)-activated protein kinase whereas rosiglitazone increased chromosome ten level. Although high insulin and glucose concentrations promoted chemoresistance, the combination of metformin or rosiglitazone with gemcitabine or doxorubicin, resulted in an additional decrease in live cancer cells and increase in apoptosis. In contrast, exenatide did not have direct effect on cancer cells. In conclusion, different types of antidiabetic pharmacotherapy had a differential direct impact on cancer cells. This study provides experimental evidence to support further investigation of metformin and rosiglitazone as first-line therapies for type 2 diabetes in cancer patients.
Feng
Yin-Hsun
YH
Department of Oncology, Chi-Mei Medical Center, Tainan, Republic of China.
Velazquez-Torres
Guermarie
G
Gully
Christopher
C
Chen
Jian
J
Lee
Mong-Hong
MH
Yeung
Sai-Ching Jim
SC
D017209:Apoptosis / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000494:pharmacology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000473:pathology*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D004357:Drug Synergism; D005947:Glucose / Q000494:pharmacology; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D007328:Insulin / Q000494:pharmacology; D008687:Metformin / Q000494:pharmacology; D009369:Neoplasms / Q000473:pathology*; D010190:Pancreatic Neoplasms / Q000473:pathology; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology; D000093542:Gemcitabine
D007004:Hypoglycemic Agents; D007328:Insulin; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D003841:Deoxycytidine; D008687:Metformin; D005947:Glucose; D000093542:Gemcitabine
Am J Epidemiol. 2004 Jun 15;159(12):1160-7
15191933
JAMA. 1995 May 24-31;273(20):1605-9
7745774
World J Surg. 2001 Apr;25(4):503-8
11396427
Cell Cycle. 2009 Jan 15;8(2):268-77
19164938
Diabetes Care. 2006 Feb;29(2):254-8
16443869
Mol Cell. 2005 Apr 29;18(3):283-93
15866171
Mol Med. 2008 Jul-Aug;14(7-8):403-11
18475308
Crit Rev Oncol Hematol. 2008 Jul;67(1):1-7
18343152
Eur J Surg. 1993 Feb;159(2):101-7
8098623
Eur J Cancer Prev. 2007 Feb;16(1):83-9
17220709
Diabetes Care. 2009 Jan;32(1):193-203
18945920
Nat Clin Pract Oncol. 2005 Jan;2(1):48-53
16264856
Cell Mol Life Sci. 2008 Dec;65(24):3981-99
18766298
Lancet Oncol. 2005 Feb;6(2):103-11
15683819
PPAR Res. 2008;2008:904041
18670617
World J Gastroenterol. 2009 Jan 28;15(4):441-8
19152448
World J Gastroenterol. 2006 Apr 14;12(14):2229-34
16610026
Expert Opin Investig Drugs. 2005 Jun;14(6):557-68
16004588
Int J Oncol. 2003 Aug;23(2):509-17
12851703
Integr Cancer Ther. 2005 Mar;4(1):25-31
15695475
J Clin Oncol. 2009 Jul 10;27(20):3297-302
19487376
Cancer Res. 2006 Nov 1;66(21):10269-73
17062558
Pancreas. 2000 Oct;21(3):310-20
11039477
Int J Cancer. 2007 May 1;120(9):1986-92
17230509
Biochem Pharmacol. 2000 Sep 15;60(6):839-49
10930539
JAMA. 2005 Dec 14;294(22):2872-8
16352795
Int J Cancer. 2006 May 15;118(10):2390-8
16425225
J Surg Res. 1995 Jun;58(6):754-8
7791356
Cancer Ther. 2008;6(A):25-34
19079765
Mol Cell Biol. 2002 Oct;22(20):7004-14
12242281
Diabetes. 1995 Nov;44(11):1249-58
7589820
Br J Cancer. 2001 Feb 2;84(3):417-22
11161410
Expert Opin Investig Drugs. 2006 Sep;15(9):1039-49
16916271
Cancer Res. 2009 Oct 1;69(19):7507-11
19752085
Cancer Lett. 2009 Apr 18;276(2):119-24
18790559
Diabetes Care. 2003 Apr;26(4):1047-51
12663571
Cell Mol Life Sci. 2007 May;64(10):1290-302
17447005
World J Gastroenterol. 2008 Dec 21;14(47):7192-8
19084933
Surgery. 1995 Aug;118(2):453-7; discussion 457-8
7638764